Feasibility of an Art-based Intervention to Address Clinician Stigma and Improve Care for Neonatal Opioid Withdrawal Syndrome

基于艺术的干预措施解决临床医生耻辱并改善新生儿阿片类药物戒断综合症护理的可行性

基本信息

项目摘要

Project Summary Clinician stigma toward mothers with opioid use histories adversely affects implementation of evidence-based care and, subsequently, infant outcomes. Our preliminary research found 54.5% of perinatal nurses had heightened stigmatizing attitudes toward perinatal opioid use and neonatal opioid withdrawal syndrome. This is concerning because every 15 minutes a newborn suffers from opioid withdrawal in the United States and the rate of perinatal opioid use is steadily increasing. Improving clinical care and outcomes for opioid-exposed mothers and infants is considered a top clinical and public health priority. Numerous studies recommend perinatal nurses engage and support mothers with opioid use disorders to deliver interventions (breastfeeding, skin-to-skin care, rooming-in) that improve short and long-term infant health outcomes (eg, withdrawal symptom severity, length of hospitalization). However, the implementation of these efforts is stymied by nurse stigmatizing attitudes related to perinatal opioid use. Toward the goal of improving infant health by addressing stigmatizing attitudes, PI Shuman developed DAB-RN (Drugs, Art, and Babies for Registered Nurses), an art-based intervention informed by Corrigan’s model of stigma and the Emancipatory Theory of Compassion. Art has long been used to facilitate attitudinal change and motivate behavioral change and DAB-RN applies artwork and art pedagogy to improve attitudes about perinatal opioid use and, thus improve infant care and health outcomes. In our preliminary testing, DAB-RN improved self-reported attitudes toward perinatal opioid use and all participants reported high satisfaction with the intervention. After conducting two focus groups, we found that the intervention is severely limited by its current delivery format – a synchronous, group-delivered program led by a facilitator – and must be adapted to a more scalable, sustainable, and testable platform. We use the ADAPT-ITT 8-phase model to adapt DAB-RN. We have completed phases 1-3 in our preliminary work. For this R21 proposal, we will complete phases 4-8. We will address barriers and concerns noted in our preliminary testing by adapting DAB-RN to a web-based intervention for asynchronous, remote delivery. Then, we will theater test the program with a diverse sample of 24 nurses and 4 topic experts, soliciting attitudes and feedback on the look, flow, usability, and content of the intervention. Findings will be used to modify the DAB-RN intervention (Aim 1). Then we will test the feasibility of the adapted DAB-RN intervention in a pilot cluster randomized trial with two arms: 1) experimental group receiving the adapted DAB-RN intervention (N=75) and 2) control group not receiving any intervention (N=75) (Aim 2). From the experimental group, we will examine feasibility including acceptability, adaptation, practicality, study logistics (recruitment, retention), and cost (production, site maintenance). We will conduct 10 in-depth interviews with nurses in the experimental arm to more comprehensively assess feasibility. We will measure nurse stigmatizing attitudes at baseline and 3-months following the intervention to identify direction of intervention effects to inform a future large cluster randomized control trial evaluating DAB-RN’s efficacy. The proposed research is significant and fits well with NIH priorities, including addressing maternal morbidity (IMPROVE Initiative) and substance use (HEAL Initiative). This study will lead to a scalable version of DAB-RN primed for a series of large-scale studies evaluating efficacy and effectiveness.
项目概要 临床医生对有阿片类药物使用史的母亲的耻辱会对循证护理的实施产生不利影响, 随后,我们的初步研究发现,54.5% 的围产期护士患有哮喘病。 对围产期阿片类药物使用和新生儿阿片类药物戒断综合征的态度这一点令人担忧,因为每 15 分钟就有一次。 在美国,一名新生儿患有阿片类药物戒断,并且围产期阿片类药物使用率正在稳步上升。 改善阿片类药物暴露母亲和婴儿的临床护理和结果被认为是临床和公共卫生的首要任务 许多研究建议围产期护士参与并支持患有阿片类药物使用障碍的母亲分娩。 改善短期和长期婴儿健康结果的干预措施(母乳喂养、肌肤接触护理、同室)(例如, 戒断症状的严重程度、住院时间)然而,这些努力的实施受到护士的阻碍。 与围产期阿片类药物使用相关的污名化态度,以通过解决污名化问题来改善婴儿健康的目标。 为了改变态度,PI S human 开发了 DAB-RN(注册护士的药物、艺术和婴儿),这是一种基于艺术的干预措施 科里根的耻辱模型和同情艺术的解放理论长期以来一直被用来促进。 态度改变和动机行为改变和 DAB-RN 应用艺术品和艺术教育学来改善态度 在我们的初步测试中,DAB-RN 改善了围产期阿片类药物的使用,从而改善婴儿护理和健康结果。 自我报告对围产期阿片类药物使用的态度,所有参与者都对干预后表示高度满意。 通过两次焦点小组讨论,我们发现干预措施受到当前交付形式的严重限制—— 由协调员领导的同步、小组交付的程序,并且必须适应更具可扩展性、可持续性和可测试性 我们使用 ADAPT-ITT 8 阶段模型来适应 DAB-RN,我们已经完成了初步阶段 1-3。 对于此 R21 提案,我们将完成第 4-8 阶段。我们将解决初步报告中指出的障碍和问题。 通过使 DAB-RN 适应基于网络的异步远程交付干预来进行测试 然后,我们将进行剧场测试。 该计划由 24 名护士和 4 名主题专家组成的不同样本组成,征求有关外观、流程、可用性、 干预措施的内容和结果将用于修改 DAB-RN 干预措施(目标 1)。 改编后的 DAB-RN 干预在具有两个组的试点集群随机试验中的可行性:1)实验组 接受适应的 DAB-RN 干预 (N=75) 和 2) 对照组不接受任何干预 (N=75)(目标 2)。 从实验组中,我们将审查可行性,包括可接受性、适应性、实用性、研究逻辑 (招聘、保留)和成本(生产、现场维护)我们将对护士进行 10 次深度访谈。 实验组更全面地评估可行性。我们将测量护士的侮辱态度。 干预后 3 个月确定干预效果的方向,为未来的大型集群随机化提供信息 评估 DAB-RN 功效的对照试验很重要,并且非常符合 NIH 的优先事项,包括。 解决孕产妇发病率(IMPROVE 倡议)和药物使用(HEAL 倡议)。 DAB-RN 版本准备用于评估功效和效果的一系列大规模研究。

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Integrating Neonatal Intensive Care Into a Family Birth Center: Describing the Integrated NICU (I-NIC).
将新生儿重症监护纳入家庭生育中心:描述综合新生儿重症监护室 (I-NIC)。
  • DOI:
  • 发表时间:
    2023-09-28
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Shuman, Clayton J;Morgan, Mikayla;Vance, Ashlee
  • 通讯作者:
    Vance, Ashlee
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Clayton John Shuman其他文献

Clayton John Shuman的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Clayton John Shuman', 18)}}的其他基金

Feasibility of an Art-based Intervention to Address Clinician Stigma and Improve Care for Neonatal Opioid Withdrawal Syndrome
基于艺术的干预措施解决临床医生耻辱并改善新生儿阿片类药物戒断综合症护理的可行性
  • 批准号:
    10348928
  • 财政年份:
    2022
  • 资助金额:
    $ 23.4万
  • 项目类别:
Mom is medicine: Implementing maternal-delivered nonpharmacologic care for neonatal opioid withdrawal
妈妈就是药:对新生儿阿片类药物戒断实施产妇非药物护理
  • 批准号:
    10448783
  • 财政年份:
    2022
  • 资助金额:
    $ 23.4万
  • 项目类别:
Mom is medicine: Implementing maternal-delivered nonpharmacologic care for neonatal opioid withdrawal
妈妈就是药:对新生儿阿片类药物戒断实施产妇非药物护理
  • 批准号:
    10653203
  • 财政年份:
    2022
  • 资助金额:
    $ 23.4万
  • 项目类别:

相似国自然基金

多氯联苯与机体交互作用对生物学年龄的影响及在衰老中的作用机制
  • 批准号:
    82373667
  • 批准年份:
    2023
  • 资助金额:
    49 万元
  • 项目类别:
    面上项目
基于年龄和空间的非随机混合对性传播感染影响的建模与研究
  • 批准号:
    12301629
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
母传抗体水平和疫苗初种年龄对儿童麻疹特异性抗体动态变化的影响
  • 批准号:
    82304205
  • 批准年份:
    2023
  • 资助金额:
    20 万元
  • 项目类别:
    青年科学基金项目
运动状态下代谢率的年龄变化特征及对人体热舒适的影响研究
  • 批准号:
  • 批准年份:
    2022
  • 资助金额:
    54 万元
  • 项目类别:
    面上项目
基于堆叠式集成学习探索人居环境对生物学年龄的影响
  • 批准号:
  • 批准年份:
    2022
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Executive functions in urban Hispanic/Latino youth: exposure to mixture of arsenic and pesticides during childhood
城市西班牙裔/拉丁裔青年的执行功能:童年时期接触砷和农药的混合物
  • 批准号:
    10751106
  • 财政年份:
    2024
  • 资助金额:
    $ 23.4万
  • 项目类别:
The Proactive and Reactive Neuromechanics of Instability in Aging and Dementia with Lewy Bodies
衰老和路易体痴呆中不稳定的主动和反应神经力学
  • 批准号:
    10749539
  • 财政年份:
    2024
  • 资助金额:
    $ 23.4万
  • 项目类别:
Identifying and testing a tailored strategy to achieve equity in blood pressure control in PACT
确定并测试量身定制的策略,以在 PACT 中实现血压控制的公平性
  • 批准号:
    10538513
  • 财政年份:
    2023
  • 资助金额:
    $ 23.4万
  • 项目类别:
RP1 Screen 2 Prevent
RP1 屏蔽 2 预防
  • 批准号:
    10595901
  • 财政年份:
    2023
  • 资助金额:
    $ 23.4万
  • 项目类别:
Stopping Hydroxychloroquine In Elderly Lupus Disease (SHIELD)
停止使用羟氯喹治疗老年狼疮病 (SHIELD)
  • 批准号:
    10594743
  • 财政年份:
    2023
  • 资助金额:
    $ 23.4万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了